Meta-analysis of the efficacy of tyrosine kinase inhibitor in radioiodine-refractory differentiated thyroid carcinoma
10.3969/j.issn.1673-9701.2024.01.006
- VernacularTitle:酪氨酸激酶抑制剂对放射性碘难治性分化型甲状腺癌疗效的Meta分析
- Author:
Cui NI
1
;
Jingyang SU
2
;
Shengyou LIN
3
Author Information
1. Department of Oncology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou 310007, Zhejiang, China
2. Department of Oncology, Tongde Hospital of Zhejiang Province, Hangzhou 310012, Zhejiang, China
3. Department of Oncology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310003, Zhejiang, China
- Publication Type:Journal Article
- Keywords:
Tyrosine kinase inhibitor;
Radioiodine-refractory differentiated thyroid carcinoma;
Efficacy;
Adverse events;
Meta-analysis
- From:
China Modern Doctor
2024;62(1):22-27
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of tyrosine kinase inhibitor(TKI)on radioiodine-refractory differentiated thyroid carcinoma(RAI-rDTC).Methods Literature related to RAI-rDTC was retrieved from Wanfang Data,CNKI,VIP,PubMed,Cochrane,EmBase and Medline databases until December 31,2021.Literature quality and experimental bias were referred to the Cochrane quality risk assessment table,and Meta-analysis was performed using RevMan 5.3 software.Results A total of 1384 patients were included in 6 studies.The results of Meta-analysis showed that the median progress free survive(HR=0.30,95%CI:0.18-0.50,P<0.00001)and overall survival(HR=0.70,95%CI:0.57-0.88,P=0.002)in treatment group were significantly longer than those in control group.There was no significant difference in complete response between two groups(RR=3.31,95%CI:0.41-26.89,P=0.26).The partial response in treatment group was significantly higher than that in control group(RR=15.97,95%CI:3.48-73.17,P=0.0004).The incidence of TKI-related adverse reactions above grade 3 in treatment group was significantly higher than that in control group(RR=2.91,95%CI:1.70-4.96,P<0.0001).Conclusion TKI can significantly prolong progress free survive and overall survival in patients with RAI-rDTC,but there are still many adverse reactions.It is necessary to comprehensively evaluate the health status of patients before medication.
